NFLD - Typical Overreaction
Dew - One can never be sure however in this case;
1) The WSJ article is referencing a prior study that took place years ago.
2) The present study appears to be going very well. I'm sure that the FDA is watching closer than ever based on the issues related to study #1.
3) FDA must have agreed that the first study deaths related to problems with how doctors "prescribed" the product versus the product itself (resulting in too much liquid being pumped into the body). The current study seems to be confirming this.
4) The product doesn't have a viable alternative that is relatively risk free. It will also provide a significant solution to the "supply & demand" issues currently being faced.
Bottom line is that management screwed up in their lack of communication. The deaths apparently were not the result of the drug, but more likely the result of misapplication by doctors. My sense is that the current study, and ultimate results, will quickly over shadow the WSJ article. In fact, the current article may help bring in investors that were previously unaware of the companies potential.
I picked up a nice chunk of shares this morning in the low $9.90's. Still predict back to $12 in a week (though I've been wrong before..!!).
Market Data 
Markets 
AI
